Adap­ti­m­mune 'ready for prime­time' as it pre­pares to launch T cell ther­a­py for sar­co­ma, CEO Adri­an Raw­cliffe says

Philadel­phia’s Adap­ti­m­mune isn’t new to the biotech scene, but CEO Adri­an Raw­cliffe says the com­pa­ny is fi­nal­ly “ready for prime­time.”

Ahead of a Thurs­day pre­sen­ta­tion at JP Mor­gan on the cell ther­a­py com­pa­ny’s five-year plan, Raw­cliffe told End­points News he’s ex­cit­ed to be in a po­si­tion that “very few biotech CEOs ac­tu­al­ly get to be in.”

“I can say that next year we’ll be launch­ing our first prod­uct. And I think that’s par­tic­u­lar­ly an achieve­ment giv­en it’s a com­plete­ly home­grown prod­uct,” he said. “It’ll be the first en­gi­neered T cell ther­a­py for a sol­id tu­mor in syn­ovial sar­co­ma with ADP-A2M4. And prob­a­bly the sec­ond cel­lu­lar prod­uct, full stop, in the sol­id tu­mor set­ting. And it’s just in­cred­i­bly ex­cit­ing, and it’s al­so it’s a per­fect­ly-sized op­por­tu­ni­ty for us.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER